BMEA · NASDAQ · Biotechnology

Biomea Fusion (BMEA)

Develops oral small-molecule medicines for diabetes and obesity.

$1.92
Pre-market−0.02 (−0.78%)
At close$1.94(+7.50%)

Something off on this page? Send us feedback.

Next report
Nov 3, 2026
estimated · in 61 days
EPS estimate
−$0.21
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.80−$0.51−$0.27−$0.64−$0.17−$0.12−$0.12Pending
Estimate−$0.84−$0.59−$0.26−$0.25−$0.24−$0.22−$0.22−$0.21
Surprise+4.8%+13.6%−3.8%−156.0%+29.2%+46.3%+46.3%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.21
Aug 2026−$0.22−$0.12+46.3%
Aug 2026−$0.22−$0.12+46.3%
Aug 2026−$0.22
May 2026−$0.24−$0.17+29.2%
Mar 2026−$0.25−$0.64−156.0%

The latest year is open to everyone — the 23 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Oct 2024
Jul 2024
May 2024
Apr 2024
Oct 2023
Jul 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Apr 2021
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 3, 2026−$0.21
Aug 6, 2026−$0.22−$0.12+46.3%+0.8%
Aug 5, 2026−$0.22−$0.12+46.3%−0.8%
Aug 4, 2026−$0.22
May 11, 2026−$0.24−$0.17+29.2%+0.6%
Mar 24, 2026−$0.25−$0.64−156.0%+8.0%

The latest year is open to everyone — the 23 quarters behind it read with an account.

Sign in
Nov 4, 2025
Aug 5, 2025
May 5, 2025
Mar 31, 2025
Oct 29, 2024
Jul 31, 2024
May 2, 2024
Apr 1, 2024
Oct 30, 2023
Jul 31, 2023
May 2, 2023
Mar 28, 2023
Nov 7, 2022
Aug 1, 2022
May 16, 2022
Feb 28, 2022
Nov 3, 2021
Aug 11, 2021
May 27, 2021
Apr 19, 2021
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020